Ocugen vs Prime Medicine
OCGN and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OCGN and PRME compare
Prime Medicine is the larger company, worth 2.8 times as much as Ocugen ($774M against $281M).
Prime Medicine scores higher on the StockData Score (5 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OCGN | PRME |
|---|---|---|
| Size and price | ||
| Market cap | $281M | $774M |
| Share price | $0.828 | $4.27 |
| Change, 1 year | −38.2% | 20.3% |
| Change, 5 years | −89.3% | −79.8% |
| Beta (5Y) | 1.65 | 0.43 |
| Employees | 116 | 146 |
| StockData Score | ||
| Total score | 1 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 91.8× |
| FCF yield | −22.8% | −20.5% (better) |
| Growth | ||
| Revenue growth, 5Y average | 152% (better) | −2.3% |
| Profitability | ||
| Return on equity | – | −207% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −6.8× | – |
| Current ratio | 0.77 | 1.79 (better) |
| Altman Z-score | −6.98 (better) | −7.06 |
| Piotroski F-score | 0 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 42.8% | 58.8% |
| Held by insiders | 2.4% | 18.6% |
| Insider net buying, 12 months | −$1.1M | – |
| Short interest, % of float | 32.5% | 19.7% |
Go deeper
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
- PRME stock overview
- PRME income statement
- PRME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.